Abcellera Biologics INC. (ABCL) — SEC Filings

Overview

Abcellera Biologics INC. (ABCL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 12, 2025: AbCellera Biologics Inc. announced on November 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of a director and the election of a new director, along with updates to the compensatory arrangements for certain officers.

Sentiment Summary

Across 26 filings, the sentiment breakdown is: 3 bearish, 23 neutral. The dominant filing sentiment for Abcellera Biologics INC. is neutral.

Filing Type Overview

Abcellera Biologics INC. (ABCL) has filed 12 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (26)

• 8-K Filing — 8-K · Dec 18, 2025
• 8-K Filing — 8-K · Nov 28, 2025
• AbCellera Biologics Inc. Reports Director Changes and Officer Compensation Updates — 8-K · Nov 12, 2025 Risk: low
  AbCellera Biologics Inc. announced on November 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depar
• AbCellera's Q3 Loss Widens Amid Revenue Growth, Cash Burn Continues — 10-Q · Nov 6, 2025 Risk: high
  AbCellera Biologics Inc. (ABCL) reported a net loss of $57.1 million for the three months ended September 30, 2025, an increase from a net loss of $51.1 million
• AbCellera Biologics Inc. Files 8-K — 8-K · Sep 10, 2025 Risk: low
  AbCellera Biologics Inc. filed an 8-K on September 10, 2025, reporting other events and financial statements. The company, incorporated in British Columbia with
• AbCellera Revenue Plummets 69% Amid Program Slowdown — 10-Q · Aug 7, 2025 Risk: high
  AbCellera Biologics Inc. reported a significant decrease in total revenue for Q2 2025, falling to $15.2 million from $48.7 million in Q2 2024, a 68.8% decline.
• AbCellera Biologics Inc. Files 8-K on Financials — 8-K · Aug 7, 2025 Risk: low
  AbCellera Biologics Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing also included Regulation FD
• AbCellera Biologics Inc. Files 8-K on Shareholder Matters — 8-K · Jun 13, 2025 Risk: low
  AbCellera Biologics Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details the
• AbCellera Biologics Inc. Files 8-K — 8-K · May 30, 2025 Risk: low
  AbCellera Biologics Inc. filed an 8-K on May 30, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific de
• AbCellera Biologics Inc. Files 8-K — 8-K · May 14, 2025 Risk: low
  AbCellera Biologics Inc. filed an 8-K on May 14, 2025, reporting other events and financial statements. The filing does not contain specific details about new m
• AbCellera Biologics Inc. Files 8-K — 8-K · May 13, 2025 Risk: low
  AbCellera Biologics Inc. filed an 8-K on May 13, 2025, reporting other events and financial statements. The filing pertains to the period ending May 12, 2025. T
• AbCellera Biologics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: low
  AbCellera Biologics Inc. filed its Q1 2025 10-Q report on May 8, 2025, for the period ending March 31, 2025. The company, based in Vancouver, Canada, operates i
• AbCellera Biologics Inc. Files 2024 DEF 14A — DEF 14A · Apr 29, 2025 Risk: low
  AbCellera Biologics Inc. filed its DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing provides details on executive compensatio
• 10-K Filing — 10-K · Feb 27, 2025
• AbCellera Biologics Inc. Files 8-K — 8-K · Feb 18, 2025 Risk: low
  AbCellera Biologics Inc. filed an 8-K on February 18, 2025, to report other events. The filing provides updated address information for the company, located at
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• AbCellera Biologics Files Q3 2024 10-Q — 10-Q · Nov 4, 2024 Risk: medium
  AbCellera Biologics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nin
• AbCellera Biologics Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 6, 2024 Risk: low
  AbCellera Biologics Inc. filed its quarterly report for the period ended June 30, 2024. The company, registered with the SEC under file number 001-39781, trades
• AbCellera Biologics Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jun 13, 2024 Risk: low
  AbCellera Biologics Inc. filed an 8-K on June 13, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain sp
• AbCellera Biologics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
  AbCellera Biologics Inc. (ABCL) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Revenue for the three months ended March 31, 2024, was $22.5 millio
• AbCellera Biologics Inc. Files Definitive Proxy Statement — DEF 14A · Apr 29, 2024 Risk:
  AbCellera Biologics Inc. (ABCL) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. AbCellera Biologics Inc. filed a Definitive Proxy Statement (D
• AbCellera Biologics Reports Officer Changes and Compensation — 8-K · Feb 23, 2024 Risk: low
  AbCellera Biologics Inc. filed an 8-K on February 23, 2024, reporting an event that occurred on February 16, 2024. The filing pertains to the departure or elect
• AbCellera Biologics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 20, 2024 Risk: medium
  AbCellera Biologics Inc. (ABCL) filed a Annual Report (10-K) with the SEC on February 20, 2024. AbCellera Biologics Inc. filed its 2023 Form 10-K on February 20
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Baillie Gifford Amends AbCellera Biologics Stake — SC 13G/A · Jan 29, 2024
  Baillie Gifford & Co., a prominent investment management firm, filed an amended SC 13G/A on January 29, 2024, indicating a change in their ownership of AbCeller

Risk Profile

Risk Assessment: Of ABCL's 18 recent filings, 2 were flagged as high-risk, 3 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Abcellera Biologics INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $8,955,000
• Net Income: -$57,100,000
• EPS: N/A
• Debt-to-Equity: 0.41
• Cash Position: $495,672,000
• Operating Margin: -851.8%
• Total Assets: $1,355,992,000
• Total Debt: $391,954,000

Industry Context

AbCellera operates in the highly competitive biotechnology sector, focusing on antibody-based therapeutics. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Key trends include advancements in AI-driven drug discovery, personalized medicine, and strategic partnerships between biotech firms and larger pharmaceutical companies to share risk and leverage expertise.

Top Tags

corporate-governance (4) · 10-Q (4) · Biotechnology (3) · financials (3) · sec-filing (3) · AbCellera Biologics (3) · executive-compensation (2) · Drug Discovery (2) · Net Loss (2) · SEC Filing (2)

Key Numbers

• Net Loss (Q3 2025): $57.1M — Increased from $51.1M in Q3 2024, indicating widening losses.
• Net Loss (YTD Sep 2025): $137.5M — Increased from $128.6M in YTD Sep 2024, showing continued unprofitability.
• Total Revenue (Q3 2025): $8.96M — Increased from $6.51M in Q3 2024, driven by research fees.
• Total Revenue (YTD Sep 2025): $30.28M — Increased from $23.78M in YTD Sep 2024, boosted by licensing revenue.
• Cash, Cash Equivalents, and Marketable Securities: $495.67M — Decreased from $625.61M at Dec 31, 2024, reflecting significant cash burn.
• Total Operating Expenses (Q3 2025): $85.23M — Decreased from $100.17M in Q3 2024, primarily due to lower depreciation.
• Depreciation, Amortization, and Impairment (Q3 2025): $5.25M — Significantly down from $36.92M in Q3 2024, impacting operating expenses.
• Common Shares Outstanding: 299,335,048 — As of November 3, 2025, indicating potential for dilution.
• SEC File Number: 001-39781 — Identifies the company's filing with the SEC.
• Q2 2025 Total Revenue: $15.2M — 68.8% decrease from Q2 2024's $48.7M
• Q2 2025 Net Loss: $35.5M — Increased from $1.2M net loss in Q2 2024
• Q2 2025 Research Fees: $10.1M — Down from $39.5M in Q2 2024
• Q2 2025 Milestone Payments: $5.1M — Down from $9.2M in Q2 2024
• YTD 2025 Total Revenue: $30.1M — Down from $95.5M in YTD 2024
• YTD 2025 Net Loss: $68.9M — Increased from $1.8M net loss in YTD 2024

Related Companies

SDGR

Frequently Asked Questions